12 research outputs found

    Insanity as a Defense to the Civil Fraud Penalty

    Get PDF
    Most neurological diseases are associated with chronic inflammation initiated by the activation of microglia, which produce cytotoxic and inflammatory factors. Signal transducers and activators of transcription (STATs) are potent regulators of gene expression but contribution of particular STAT to inflammatory gene expression and STAT-dependent transcriptional networks underlying brain inflammation need to be identified. In the present study, we investigated the genomic distribution of Stat binding sites and the role of Stats in the gene expression in lipopolysaccharide (LPS)-activated primary microglial cultures. Integration of chromatin immunoprecipitation-promoter microarray data and transcriptome data revealed novel Stat-target genes including Jmjd3, Ccl5, Ezr, Ifih1, Irf7, Uba7, and Pim1. While knockdown of individual Stat had little effect on the expression of tested genes, knockdown of both Stat1 and Stat3 inhibited the expression of Jmjd3 and inflammatory genes. Transcriptional regulation of Jmjd3 by Stat1 and Stat3 is a novel mechanism crucial for launching inflammatory responses in microglia. The effects of Jmjd3 on inflammatory gene expression were independent of its H3K27me3 demethylase activity. Forced expression of constitutively activated Stat1 and Stat3 induced the expression of Jmjd3, inflammation-related genes, and the production of proinflammatory cytokines as potently as lipopolysacharide. Gene set enrichment and gene function analysis revealed categories linked to the inflammatory response in LPS and Stat1C + Stat3C groups. We defined upstream pathways that activate STATs in response to LPS and demonstrated contribution of Tlr4 and Il-6 and interferon-. signaling. Our findings define novel direct transcriptional targets of Stat1 and Stat3 and highlight their contribution to inflammatory gene expression

    The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia

    No full text
    Most neurological diseases are associated with chronic inflammation initiated by the activation of microglia, which produce cytotoxic and inflammatory factors. Signal transducers and activators of transcription (STATs) are potent regulators of gene expression but contribution of particular STAT to inflammatory gene expression and STAT-dependent transcriptional networks underlying brain inflammation need to be identified. In the present study, we investigated the genomic distribution of Stat binding sites and the role of Stats in the gene expression in lipopolysaccharide (LPS)-activated primary microglial cultures. Integration of chromatin immunoprecipitation-promoter microarray data and transcriptome data revealed novel Stat-target genes including Jmjd3, Ccl5, Ezr, Ifih1, Irf7, Uba7, and Pim1. While knockdown of individual Stat had little effect on the expression of tested genes, knockdown of both Stat1 and Stat3 inhibited the expression of Jmjd3 and inflammatory genes. Transcriptional regulation of Jmjd3 by Stat1 and Stat3 is a novel mechanism crucial for launching inflammatory responses in microglia. The effects of Jmjd3 on inflammatory gene expression were independent of its H3K27me3 demethylase activity. Forced expression of constitutively activated Stat1 and Stat3 induced the expression of Jmjd3, inflammation-related genes, and the production of proinflammatory cytokines as potently as lipopolysacharide. Gene set enrichment and gene function analysis revealed categories linked to the inflammatory response in LPS and Stat1C + Stat3C groups. We defined upstream pathways that activate STATs in response to LPS and demonstrated contribution of Tlr4 and Il-6 and interferon-. signaling. Our findings define novel direct transcriptional targets of Stat1 and Stat3 and highlight their contribution to inflammatory gene expression

    Cleavage of Hyaluronan and CD44 Adhesion Molecule Regulate Astrocyte Morphology via Rac1 Signalling

    No full text
    <div><p>Communication of cells with their extracellular environment is crucial to fulfill their function in physiological and pathophysiological conditions. The literature data provide evidence that such a communication is also important in case of astrocytes. Mechanisms that contribute to the interaction between astrocytes and extracellular matrix (ECM) proteins are still poorly understood. Hyaluronan is the main component of ECM in the brain, where its major receptor protein CD44 is expressed by a subset of astrocytes. Considering the fact that functions of astrocytes are tightly coupled with changes in their morphology (e.g.: glutamate clearance in the synaptic cleft, migration, astrogliosis), we investigated the influence of hyaluronan cleavage by hyaluronidase, knockdown of CD44 by specific shRNA and CD44 overexpression on astrocyte morphology. Our results show that hyaluronidase treatment, as well as knockdown of CD44, in astrocytes result in a “stellate”-like morphology, whereas overexpression of CD44 causes an increase in cell body size and changes the shape of astrocytes into flattened cells. Moreover, as a dynamic reorganization of the actin cytoskeleton is supposed to be responsible for morphological changes of cells, and this reorganization is controlled by small GTPases of the Rho family, we hypothesized that GTPase Rac1 acts as a downstream effector for hyaluronan and CD44 in astrocytes. We used FRET-based biosensor and a dominant negative mutant of Rac1 to investigate the involvement of Rac1 activity in hyaluronidase- and CD44-dependent morphological changes of astrocytes. Both, hyaluronidase treatment and knockdown of CD44, enhances Rac1 activity while overexpression of CD44 reduces the activity state in astrocytes. Furthermore, morphological changes were blocked by specific inhibition of Rac1 activity. These findings indicate for the first time that regulation of Rac1 activity is responsible for hyaluronidase and CD44-driven morphological changes of astrocytes.</p></div

    Deactivation of Rac1 activity rescues CD44 knockdown and hyaluronidase-induced morphological changes of astrocytes.

    No full text
    <p>A: Representative images of astrocytes transfected with CD44shRNA/pSuper or co-transfected with pcDNA3-EGFP-Rac1-T17N (Rac1-DN) constructs. The β-actin-RFP construct was used for cell visualization. Scale: 20 μm. B: Morphometric analysis of shape-describing parameters of cells treated as in A. One way ANOVA, area: F(3.112) = 2.456, p>0,05, solidity: F(3.114) = 30.173, p<0.001 Sidak post hoc test, circularity: F(3.114) = 13.834, p<0.001, branching: F(3.114) = 51, 825, p<0,001. Dunnett’s C post hoc test. C: Representative images of astrocytes transfected with pcDNA3-EGFP-Rac1-T17N (Rac1-DN) and β-actin-RFP constructs and treated with hyaluronidase. Scale: 20 μm. D: Morphometric analysis of shape-describing parameters of cells treated as in C. One way ANOVA, area: F(2.147) = 1.520, p>0.05, solidity: F(2.147) = 106.292, p<0.001, circularity: F(2.147) = 96.843, p<0.001, branching: F(2.147) = 135.932; p<0,001, Dunnett’s C post hoc tests.</p

    Hyaluronidase treatment and CD44-knockdown leads to enhanced Rac1 activity.

    No full text
    <p>A: Cells were transfected with FRET based biosensor pRaichu-Rac1/1011X and then treated or not with hyaluronidase for 24h. YFP-CFP ratio was calculated as a readout of Rac1 activity. T-Student test, t(589) = 3.212; p<0,001. B: Cells were co-transfected with pRaichu-Rac1/1011X and pSuper/CD44shRNA/CD44-RFP constructs. YFP-CFP ratio was calculated as a readout of Rac1 activity. One way ANOVA, F(2.527) = 39.998; p<0.001, Sidak post hoc test.</p

    Astrocytes treated with hyaluronidase acquire the stellate-like morphology.

    No full text
    <p>A. Hyaluronan digestion by hyaluronidase was evaluated by staining with hyaluronan binding protein (HABP) (red). Scale: 30 μm. B. Measurement of fluorescence intensity. One way ANOVA test was performed, F(2.57) = 53.169; p<0.001, Dunnett’s C post hoc. C. Representative images of astrocytes transfected with β-actin GFP and either untreated (control) or treated with hyaluronidase or heat inactivated hyaluronidase for 48h. Cell nuclei were visualized with DAPI staining. Scale: 30 μm.D. Morphometric analysis of shape-describing parameters of cells treated as described in C. One way ANOVA test was performed, area: F(2.57) = 2.658; p>0.05, solidity: F(2.57) = 16.814; p<0.001, circularity: F(2.57) = 13.799; p<0.001, branching: F(2.57) = 16.774; p<0,001 Dunnett’s C post hoc test.</p

    CD44 regulates astrocyte morphology.

    No full text
    <p>A: Validation of CD44shRNA and CD44-GFP constructs. Astrocytes were transfected with pSuper, CD44shRNA or CD44-GFP constructs (together with β-actin-GFP plasmid) and then immunostained with anti-CD44 antibody (red). The level of CD44 expression was evaluated by measuring CD44 immunofluorescence (IF) signal intensity with the use of ImageJ program. One way ANOVA, F(2.71) = 71.187, p<0.001, Dunnett C post hoc tests. Scale: 30 μm. B: Morphological analysis of shape-describing parameters of astrocytes in 2D cultures co-transfected with pSuper, CD44shRNA or CD44shRNA/CD44Rescue constructs together with β-actin-GFP plasmid. One way ANOVA test was performed, area: F(3.150) = 8.169; p<0.001, solidity: F(3.153) = 21.454; p<0.001, circularity: F(3.153) = 18.873; p<0.001, Dunnett’s C post hoc tests, branching: F(3.151) = 33,478; p<0.001, Sidak post hoc test. Scale: 30 μm. C: The morphological analysis of shape-describing parameters of astrocytes in 3D cultures transfected with pSuper or CD44shRNA constructs (together with β-actin-GFP plasmid) or CD44-GFP. One way ANOVA test was performed, area: F(2.92) = 12.311; p<0.001, Sidak post hoc test; solidity: F(2.95) = 42.208; p<0.001, Dunnett’s C post hoc test, circularity: F(2.94) = 20.609; p<0.001, Dunnett’s C post hoc test, branching: F(2.95) = 17.703; p<0.001, Sidak post hoc test. Scale: 30 μm.</p

    H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells

    No full text
    Summary: Diffuse intrinsic pontine gliomas (DIPGs) are deadly pediatric brain tumors, non-resectable due to brainstem localization and diffusive growth. Over 80% of DIPGs harbor a mutation in histone 3 (H3.3 or H3.1) resulting in a lysine-to-methionine substitution (H3K27M). Patients with DIPG have a dismal prognosis with no effective therapy. We show that histone deacetylase (HDAC) inhibitors lead to a significant reduction in the H3.3K27M protein (up to 80%) in multiple glioma cell lines. We discover that the SB939-mediated H3.3K27M loss is partially blocked by a lysosomal inhibitor, chloroquine. The H3.3K27M loss is facilitated by co-occurrence of H2A.Z, as evidenced by the knockdown of H2A.Z isoforms. Chromatin immunoprecipitation sequencing (ChIP-seq) analysis confirms the occupancy of H3.3K27M and H2A.Z at the same SB939-inducible genes. We discover a mechanism showing that HDAC inhibition in DIPG leads to pharmacological modulation of the oncogenic H3.3K27M protein levels. These findings show the possibility of directly targeting the H3.3K27M oncohistone
    corecore